1 Interstitial Lung Diseases Center of Excellence, Department of Pulmonology, St Antonius Hospital, Nieuwegein, Netherlands; Department of Pharmacology and Toxicology, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, Netherlands; ild care foundation research team, 6711 NR Ede, Netherlands; World Association for Sarcoidosis and Other Granulomatous Disorders, Padova, Italy. Electronic address: m.drent@ildcare.nl.
2 Institute of Clinical Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK; Birmingham Regional NHS ILD and Occupational Lung Disease Service, University Hospitals Birmingham NHS Foundation Trust, UK; Department of Health and Care Professions, Faculty of Health and Life Sciences, University of Exeter, Exeter, UK; World Association for Sarcoidosis and Other Granulomatous Disorders, Padova, Italy.
3 New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, USA; University Medical Center, Comprehensive Pulmonary Hypertension Center and Interstitial Lung Disease Clinic Programs, New Orleans, LA, USA; Tulane University School of Medicine, New Orleans, LA, USA; Louisiana State University Health Sciences Center, Division of Pulmonary Medicine, New Orleans, LA, USA; World Association for Sarcoidosis and Other Granulomatous Disorders, Padova, Italy.
4 Respiratory Disease Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy; World Association for Sarcoidosis and Other Granulomatous Disorders, Padova, Italy.
5 Interstitial Lung Diseases Center of Excellence, Department of Pulmonology, St Antonius Hospital, Nieuwegein, Netherlands; Division of Heart and Lungs, University Medical Center, Utrecht, Netherlands; World Association for Sarcoidosis and Other Granulomatous Disorders, Padova, Italy.
6 Royal Brompton Hospital, Imperial College London, London, UK; World Association for Sarcoidosis and Other Granulomatous Disorders, Padova, Italy.